Cargando…

Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin(®)) in patients with advanced non-squamous non-small cell lung cancer

PURPOSE: The objectives of this analysis were to characterize the population pharmacokinetics (PK) of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin(®)) sourced from the European Union (bevacizumab-EU) in patients with advanced non-squamous non-small cell lung cancer (NSCL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Cheryl S. W., Sweeney, Kevin, Cronenberger, Carol
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036079/ https://www.ncbi.nlm.nih.gov/pubmed/31768697 http://dx.doi.org/10.1007/s00280-019-03946-8

Ejemplares similares

Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)
por: Ingram, Rebecca L., et al.
Publicado: (2023)

PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin(®)), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study
por: Reinmuth, Niels, et al.
Publicado: (2019)

Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev(®)), a bevacizumab biosimilar, under extended in-use conditions
por: Weiser, Sarah, et al.
Publicado: (2022)

A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers
por: Knight, Beverly, et al.
Publicado: (2016)

Pharmacokinetics of intravitreal bevacizumab (Avastin(®)) in rabbits
por: Sinapis, Christos I, et al.
Publicado: (2011)

Intravitreal bevacizumab (avastin) for circumscribed choroidal hemangioma
por: Mandal, Subrata, et al.
Publicado: (2011)

Using intravitreal bevacizumab (Avastin(®)) – Indian Scenario
por: Kumar, Atul, et al.
Publicado: (2017)

Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial
por: Shi, Yuankai, et al.
Publicado: (2021)

Intravitreal Bevacizumab (Avastin) as an Adjuvant for the Treatment of Posterior Scleritis
por: Lim, Ji Won, et al.
Publicado: (2011)

Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy
por: Shaikh, Saad
Publicado: (2008)

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
por: Hummel, Matthew, et al.
Publicado: (2021)

Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis
por: Xiao, Xian, et al.
Publicado: (2022)

Intravitreal bevacizumab (Avastin) in choroidal neovascular membrane in angioid streaks
por: Sachdev, Nishant, et al.
Publicado: (2007)

Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture
por: Arevalo, J. Fernando, et al.
Publicado: (2011)

Bevacizumab (Avastin(®)) for the management of anterior chamber neovascularization and neovascular glaucoma
por: Brouzas, Dimitrios, et al.
Publicado: (2009)

Intravitreal Bevacizumab (Avastin) as an Adjuvant Treatment in Cases of Neovascular Glaucoma
por: Ghanem, Asaad A., et al.
Publicado: (2009)

Impact of Intravitreal Injection of Bevacizumab (Avastin) on Rabbit's Choroid and Retina
por: Karawya, Sherif, et al.
Publicado: (2008)

Intravitreal Bevacizumab (Avastin) as an Adjuvant Therapy for Choroidal Carcinoid Metastasis
por: Karimi, Saeed, et al.
Publicado: (2020)

Endophthalmitis After Intravitreal Bevacizumab (Avastin) Injections: An Outbreak Investigated
por: Shoaib, Khawaja K, et al.
Publicado: (2023)

Pooled analysis of three pharmacokinetic studies comparing biosimilar MB02 and reference bevacizumab
por: Miguel‐Lillo, B., et al.
Publicado: (2023)

Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study
por: Zhao, Zhiting, et al.
Publicado: (2023)

A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers
por: Shin, Donghoon, et al.
Publicado: (2020)

Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
por: Cao, Di, et al.
Publicado: (2023)

Intravitreal Bevacizumab (Avastin) Treatment of Neovascular Glaucoma in Ocular Ischemic Syndrome
por: Lee, Sang Joon, et al.
Publicado: (2009)

Acute Bilateral Endophthalmitis Following Bilateral Intravitreal Bevacizumab (Avastin) Injection
por: Tabatabaii, Ali, et al.
Publicado: (2013)

Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
por: Merz, Patrick R., et al.
Publicado: (2018)

A Randomized, Double-Blind, Single-Dose Study Comparing the Biosimilarity of HOT-1010 With Bevacizumab (Avastin®) in Chinese Healthy Male Subjects
por: Huang, Kai, et al.
Publicado: (2021)

Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population
por: Kumar, Atul, et al.
Publicado: (2007)

Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
por: Gutiérrez, Juan Carlos Mesa, et al.
Publicado: (2008)

Bevacizumab (Avastin) and Thermal Laser Combination Therapy for Peripapillary Choroidal Neovascular Membranes
por: Adrean, Sean D., et al.
Publicado: (2017)

Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario
por: Jain, Prashant, et al.
Publicado: (2017)

Charge Variants of an Avastin Biosimilar Isolation, Characterization, In Vitro Properties and Pharmacokinetics in Rat
por: Zhao, Yan-Yan, et al.
Publicado: (2016)

A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers
por: Sinn, Angela, et al.
Publicado: (2021)

SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)

Is monthly retreatment with intravitreal bevacizumab (Avastin(®)) necessary in neovascular age-related macular degeneration?
por: Ghazi, Nicola G, et al.
Publicado: (2010)

Proteins from Avastin® (bevacizumab) Show Tyrosine Nitrations for which the Consequences Are Completely Unclear
por: Wan, Jia, et al.
Publicado: (2012)

Mechanisms Controlling the Effects of Bevacizumab (Avastin) on the Inhibition of Early but Not Late Formed Corneal Neovascularization
por: Chen, Wei-Li, et al.
Publicado: (2014)

Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial
por: Verschraegen, Claire, et al.
Publicado: (2022)

Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)
por: Syrigos, Konstantinos, et al.
Publicado: (2021)

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)
por: Trukhin, Dmytro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7ca835an25k14f4ueqnf0u6het